Emerging roles of HDL in immune function
No abstract available (Source: Current Opinion in Lipidology)
Source: Current Opinion in Lipidology - November 2, 2018 Category: Lipidology Tags: BIMONTHLY UPDATE: Edited by Alan Rees Source Type: research
Intestinal cholesterol absorption
No abstract available (Source: Current Opinion in Lipidology)
Source: Current Opinion in Lipidology - November 2, 2018 Category: Lipidology Tags: BIMONTHLY UPDATE: Edited by Alan Rees Source Type: research
Mendelian randomization causally link lipoproteins to systemic atherosclerosis and help design clinical trials for the future of lipidology
No abstract available (Source: Current Opinion in Lipidology)
Source: Current Opinion in Lipidology - November 2, 2018 Category: Lipidology Tags: BIMONTHLY UPDATE: Edited by Alan Rees Source Type: research
Metabolism: The road to inflammation and atherosclerosis
Purpose of review
Evidence accumulates suggesting that cellular metabolic alterations fuel and dictate the inflammatory state of cells. In this review, we provide an overview of the observed metabolic reprogramming in endothelial cells and innate immune cells upon interaction with modified lipoproteins, thereby contributing to the progression of atherosclerosis.
Recent findings
Inflammatory endothelial cells at sites exposed to disturbed flow patterns show increased glycolytic activity. Atherogenic factors further enhance these metabolic changes by upregulating the mitochondrial energy production and thereby facilitat...
Source: Current Opinion in Lipidology - November 2, 2018 Category: Lipidology Tags: THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts Source Type: research
Colchicine: an affordable anti-inflammatory agent for atherosclerosis
Purpose of review
Inflammation has been shown to be central to the development and progression of atherosclerosis. Despite detailed understanding of its central role and the cellular dynamics, which contribute to atherosclerotic inflammation, there has been slow progress in finding suitable agents to treat it. The recent CANTOS trial showed that the interleukin-1β inhibitor canakinumab can improve outcomes after acute coronary syndromes. Being a monoclonal antibody, it is expensive and inconvenient to administer for long-term treatment. This review summarizes recent work in finding effective, affordable alternatives to ...
Source: Current Opinion in Lipidology - November 2, 2018 Category: Lipidology Tags: THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts Source Type: research
RNA-targeted therapeutics for lipid disorders
Purpose of review
To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.
Recent findings
Despite a number of approved therapies for lipid disorders, significant unmet needs are present in treating persistently elevated LDL-cholesterol, remnant-cholesterol, triglycerides and lipoprotein(a) [Lp(a)]. Small molecules and antibodies are effective modalities, but they are unable to adequately treat many patients with abnormal lipid parameters. Targeting mRNA with oligonucleotides to prevent protein translation is a relatively novel method to red...
Source: Current Opinion in Lipidology - November 2, 2018 Category: Lipidology Tags: THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts Source Type: research
Key aspects of PCSK9 inhibition beyond LDL lowering
Purpose of review
Our primary objective is to review the most recent findings on the biology of PCSK9 and on two key aspects of PCSK9 inhibition beyond LDL control of great clinical relevance: the regulation of lipoprotein (a) circulating levels by PCSK9 inhibitors and the putative diabetogenic effects of these novel therapies.
Recent findings
The reality of two distinct extracellular and intracellular pathways by which PCSK9 decreases the abundance of the LDLR at the surface of many cell types, most importantly hepatocytes, has recently been established. In contrast, the exact mechanisms by which PCSK9 inhibitors low...
Source: Current Opinion in Lipidology - November 2, 2018 Category: Lipidology Tags: THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts Source Type: research
Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?
This article highlights the SAFEHEART-RE as a model to predict incident ASCVD in familial hypercholesterolemia. This equation is a simple and widely applicable tool for use in every clinical setting. Furthermore, coronary atherosclerosis assessed by coronary computed-tomographic angiography (coronary-CTA) is independently associated to the cardiovascular risk estimated according to the SAFEHEART-RE. This equation, as well as coronary-CTA and new biomarkers, could increase individual ASCVD risk stratification and could improve the efficiency and the use of new lipid-lowering therapies in familial hypercholesterolemia. (Sour...
Source: Current Opinion in Lipidology - November 2, 2018 Category: Lipidology Tags: THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts Source Type: research
The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation
Purpose of review
We aim to outline the importance and the clinical implications of using predicted individual therapy-benefit in making patient-centered treatment decisions in cardiovascular disease (CVD) prevention. Therapy-benefit concepts will be illustrated with examples of patients undergoing lipid management.
Recent findings
In both primary and secondary CVD prevention, the degree of variation in individual therapy-benefit is large. An individual's therapy-benefit can be estimated by combining prediction algorithms and clinical trial data. Measures of therapy-benefit can be easily integrated into clinical pract...
Source: Current Opinion in Lipidology - November 2, 2018 Category: Lipidology Tags: THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts Source Type: research
Writing on the wall for precision medicine in the prevention of atherosclerotic cardiovascular disease
No abstract available (Source: Current Opinion in Lipidology)
Source: Current Opinion in Lipidology - November 2, 2018 Category: Lipidology Tags: THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts Source Type: research
Editorial introductions
No abstract available (Source: Current Opinion in Lipidology)
Source: Current Opinion in Lipidology - November 2, 2018 Category: Lipidology Tags: EDITORIAL INTRODUCTIONS Source Type: research
Emerging therapeutic potential of glycine in cardiometabolic diseases: dual benefits in lipid and glucose metabolism
No abstract available (Source: Current Opinion in Lipidology)
Source: Current Opinion in Lipidology - August 31, 2018 Category: Lipidology Tags: BIMONTHLY UPDATE: Edited by Alan Rees Source Type: research
Burning fat to keep your stem cells? The role of fatty acid oxidation in various tissue stem cells
No abstract available (Source: Current Opinion in Lipidology)
Source: Current Opinion in Lipidology - August 31, 2018 Category: Lipidology Tags: BIMONTHLY UPDATE: Edited by Alan Rees Source Type: research
Antioxidants and risk of dementia: recent insights and future opportunities
No abstract available (Source: Current Opinion in Lipidology)
Source: Current Opinion in Lipidology - August 31, 2018 Category: Lipidology Tags: BIMONTHLY UPDATE: Edited by Alan Rees Source Type: research
Non-parenchymal hepatic cell lipotoxicity and the coordinated progression of non-alcoholic fatty liver disease and atherosclerosis
Purpose of review
Non-alcoholic fatty liver disease (NAFLD) appears to be independently associated with the development of atherosclerosis. The biological mechanisms underlying this association are complex, and likely involve liver-resident cell types other than hepatocytes. Thus, we review recent evidence that non-parenchymal hepatic cell responses to lipid excess contribute to the pathogenesis of both NAFLD and atherosclerosis.
Recent findings
Significant independent associations between NAFLD and atherosclerosis have been identified through cross-sectional studies and meta-analyses. Mechanistic studies in cell cult...
Source: Current Opinion in Lipidology - August 31, 2018 Category: Lipidology Tags: ATHEROSCLEROSIS: CELL BIOLOGY AND LIPOPROTEINS: Edited by Mohamad Navab and Menno de Winther Source Type: research
